{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:35:13Z","timestamp":1789115713220,"version":"build-2803163510"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamadermatol.2018.4093","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T11:31:28Z","timestamp":1543404688000},"page":"229","source":"Crossref","is-referenced-by-count":56,"title":["Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions"],"prefix":"10.1001","volume":"155","author":[{"given":"Chloe","family":"Ekelem","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Juhasz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Khera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Howard University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Atanaskova","family":"Mesinkovska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"drv180005r1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life.","volume":"72","author":"Brown","year":"2009","journal-title":"Med Hypotheses"},{"issue":"2","key":"drv180005r2","first-page":"56","article-title":"Low-dose naltrexone for normalizing immune system function.","volume":"19","author":"Bihari","year":"2013","journal-title":"Altern Ther Health Med"},{"issue":"4","key":"drv180005r3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.mehy.2004.09.024","article-title":"Low dose naltrexone therapy in multiple sclerosis.","volume":"64","author":"Agrawal","year":"2005","journal-title":"Med Hypotheses"},{"key":"drv180005r4","first-page":"1","article-title":"Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.","volume":"2","author":"Ludwig","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"15","key":"drv180005r5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/1535370217724791","article-title":"Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.","volume":"242","author":"Ludwig","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"drv180005r6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/ajg.2007.102.issue-4","article-title":"Low-dose naltrexone therapy improves active Crohn\u2019s disease.","volume":"102","author":"Smith","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"drv180005r7","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial.","volume":"56","author":"Smith","year":"2011","journal-title":"Dig Dis Sci"},{"key":"drv180005r8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.npep.2016.06.003","article-title":"Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn\u2019s disease in rats.","volume":"59","author":"Tawfik","year":"2016","journal-title":"Neuropeptides"},{"issue":"4611","key":"drv180005r9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1126\/science.6867737","article-title":"Naltrexone modulates tumor response in mice with neuroblastoma.","volume":"221","author":"Zagon","year":"1983","journal-title":"Science"},{"key":"drv180005r10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/nyas.1987.496.issue-1","article-title":"Enkephalins and T-cell enhancement in normal volunteers and cancer patients.","volume":"496","author":"Plotnikoff","year":"1987","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"drv180005r11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.intimp.2013.10.012","article-title":"Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).","volume":"17","author":"Meng","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"drv180005r12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/apc.1995.9.3","article-title":"Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV\/AIDS.","volume":"9","author":"Bihari","year":"1995","journal-title":"AIDS Patient Care"},{"issue":"2","key":"drv180005r13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0376-8716(00)00181-2","article-title":"Opioids, opioid receptors, and the immune response.","volume":"62","author":"McCarthy","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"drv180005r14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.intimp.2016.08.015","article-title":"Functional modulation on macrophage by low dose naltrexone (LDN).","volume":"39","author":"Yi","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"drv180005r15","first-page":"1140","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris.","volume":"16","author":"Strazzulla","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"drv180005r16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/exd.2016.25.issue-8","article-title":"Opioids and skin homeostasis, regeneration and ageing: what\u2019s the evidence?","volume":"25","author":"Bigliardi","year":"2016","journal-title":"Exp Dermatol"},{"issue":"2","key":"drv180005r17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bph.2015.172.issue-2","article-title":"Activation of the d-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration.","volume":"172","author":"Bigliardi","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"5","key":"drv180005r18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/exd.2009.18.issue-5","article-title":"Opioids and the skin: where do we stand?","volume":"18","author":"Bigliardi","year":"2009","journal-title":"Exp Dermatol"},{"issue":"5","key":"drv180005r19","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Low-dose naltrexone: a novel treatment for Hailey-Hailey disease.","volume":"178","author":"Campbell","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"drv180005r20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000080150","article-title":"Methionine-enkephalin stimulates hydrogen peroxide and nitric oxide production in rat peritoneal macrophages: interaction of mu, delta and kappa opioid receptors.","volume":"11","author":"Vujic","year":"2004","journal-title":"Neuroimmunomodulation"},{"issue":"10","key":"drv180005r21","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/jamadermatol.2017.2446","article-title":"Treatment of Hailey-Hailey disease with low-dose naltrexone.","volume":"153","author":"Albers","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"drv180005r22","first-page":"533","article-title":"Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases.","volume":"41","author":"Metze","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"drv180005r23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/0024-3205(93)90581-M","article-title":"Opiates, mast cells and histamine release.","volume":"53","author":"Barke","year":"1993","journal-title":"Life Sci"},{"issue":"1","key":"drv180005r24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0733-8635(05)70239-4","article-title":"Neurotropic and psychotropic drugs in dermatology.","volume":"19","author":"Tennyson","year":"2001","journal-title":"Dermatol Clin"},{"issue":"9041","key":"drv180005r25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(96)04176-1","article-title":"Randomised crossover trial of naltrexone in uraemic pruritus.","volume":"348","author":"Peer","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"drv180005r26","doi-asserted-by":"publisher","first-page":"A249","DOI":"10.1289\/ehp.119-a248","article-title":"Questions persist: environmental factors in autoimmune disease.","volume":"119","author":"Schmidt","year":"2011","journal-title":"Environ Health Perspect"},{"issue":"3","key":"drv180005r27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","article-title":"Variable response to naltrexone in patients with Hailey-Hailey disease.","volume":"154","author":"Cao","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"10","key":"drv180005r28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease).","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"drv180005r29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2017.02.040","article-title":"Hailey-Hailey disease successfully controlled with low-dose naltrexone.","volume":"76","author":"Li","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"drv180005r30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","article-title":"Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus.","volume":"28","author":"Lee","year":"2016","journal-title":"Ann Dermatol"},{"issue":"6","key":"drv180005r31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","article-title":"Treatment of pruritus with topically applied opiate receptor antagonist.","volume":"56","author":"Bigliardi","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"drv180005r32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1034\/j.1600-0625.2002.110508.x","article-title":"Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema.","volume":"11","author":"Heyer","year":"2002","journal-title":"Exp Dermatol"},{"issue":"8","key":"drv180005r33","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/jdv.2009.23.issue-8","article-title":"Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.","volume":"23","author":"Malekzad","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"drv180005r34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/120347540500900502","article-title":"Successful treatment of refractory aquagenic pruritus with naltrexone.","volume":"9","author":"Ingber","year":"2005","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"drv180005r35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.burns.2007.10.009","article-title":"Naltrexone for the management of post-burn pruritus: a preliminary report.","volume":"34","author":"LaSalle","year":"2008","journal-title":"Burns"},{"issue":"3","key":"drv180005r36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1525-1470.2008.00699.x","article-title":"The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case.","volume":"25","author":"Chang","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"drv180005r37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"issue":"4","key":"drv180005r38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"key":"drv180005r39","doi-asserted-by":"publisher","first-page":"804296","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis.","volume":"2011","author":"Frech","year":"2011","journal-title":"Int J Rheumatol"},{"issue":"5","key":"drv180005r40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/clpt.1987.200","article-title":"Effect of naltrexone on ethanol-provoked flushing in Oriental and white subjects.","volume":"42","author":"Wilkin","year":"1987","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"drv180005r41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000077841","article-title":"A comparative study on the effects of naltrexone and loratadine on uremic pruritus.","volume":"208","author":"Legroux-Crespel","year":"2004","journal-title":"Dermatology"},{"issue":"3","key":"drv180005r42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1681\/ASN.V113514","article-title":"Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.","volume":"11","author":"Pauli-Magnus","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"drv180005r43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ajd.1997.38.issue-4","article-title":"Naltrexone: a case report of pruritus from an antipruritic.","volume":"38","author":"Sullivan","year":"1997","journal-title":"Australas J Dermatol"},{"issue":"4","key":"drv180005r44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/archdermatol.2009.4","article-title":"Chronic ulcers caused by injection of substances: healing aided by naltrexone.","volume":"145","author":"Reece","year":"2009","journal-title":"Arch Dermatol"},{"issue":"8","key":"drv180005r45","doi-asserted-by":"publisher","first-page":"1209.e3","DOI":"10.1016\/j.ajem.2017.04.012","article-title":"Potential drug interaction with opioid agonist in the setting of chronic low-dose opioid antagonist use.","volume":"35","author":"Leonard","year":"2017","journal-title":"Am J Emerg Med"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2716295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T21:39:44Z","timestamp":1662500384000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.4093"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.4093","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734522984.793559606","asserted-by":"object"}]},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}